Search Results for: carl june

Posted on

What Makes a Breakthrough? “Eight Steps Back” Before Making it to the Finish Lit

by Meagan Raeke In popular culture, scientific discovery is often portrayed in “Eureka!” moments of sudden realization: a lightbulb moment, coming sometimes by accident. But in real life—and in Penn Medicine’s rich history as a scientific innovator for more than 250 years—scientific breakthroughs can never truly be distilled down to a single, “ah-ha” moment. They’re …

Continue reading “What Makes a Breakthrough? “Eight Steps Back” Before Making it to the Finish Lit”

Posted on

Penn Medicine and Children’s Hospital of Philadelphia Announce Partnership with Costa Rica for CAR T Cell Therapy

Carl June, MD, Professor in the Perelman School of Medicine and member of the Penn Bioengineering Graduate Group, was quoted in a recent press release  announcing a new international partnership between Penn Medicine (PSOM), the Children’s Hospital of Pennsylvania (CHOP), and Costa Rica’s CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to …

Continue reading “Penn Medicine and Children’s Hospital of Philadelphia Announce Partnership with Costa Rica for CAR T Cell Therapy”

Posted on

FDA Approves Penn Pioneered CAR T Cell Therapy for Third Indication

The U.S. Food and Drug Administration has expanded its approval for Kymriah, a personalized cellular therapy developed at the Abramson Cancer Center, this time for the treatment of adults with relapsed/refractory follicular lymphoma who have received at least two lines of systemic therapy. “Patients with follicular lymphoma who relapse or don’t respond to treatment have …

Continue reading “FDA Approves Penn Pioneered CAR T Cell Therapy for Third Indication”

Posted on

Decade-long Remission After CAR T Cell Therapy

Carl H. June, the Richard W. Vague Professor in Immunotherapy in Pathology and Laboratory Medicine at Penn Medicine, director of the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, and member of the Penn Bioengineering Graduate Group at the University of Pennsylvania, has led a new analytical study published in Nature that explains the longest …

Continue reading “Decade-long Remission After CAR T Cell Therapy”

Posted on

Penn Bioengineering Celebrates Five Researchers on Highly Cited Researchers 2021 List

The Department of Bioengineering is proud to announce that five of our faculty have been named on the annual Highly Cited Researchers™ 2021 list from Clarivate: Dani S. Bassett, J. Peter Skirkanich Professor in Bioengineering and in Electrical and Systems Engineering Bassett runs the Complex Systems lab which tackles problems at the intersection of science, …

Continue reading “Penn Bioengineering Celebrates Five Researchers on Highly Cited Researchers 2021 List”

Posted on

Charting a Path Forward with Unifying Definition of Cytokine Storm

by Melissa Moody Penn Medicine researchers have developed a unifying definition of ‘cytokine storm’ to provide a framework to assess and treat patients whose immune systems have gone rogue. One of the most elusive aspects for clinicians treating COVID-19 is the body’s immune response to the virus. In the most severe cases of COVID-19, the …

Continue reading “Charting a Path Forward with Unifying Definition of Cytokine Storm”

Posted on

Avery Posey’s cancer research takes high risks for big rewards

by Melissa Moody Much of the world, including research at Penn Medicine, has focused its attention on how T cells–which play a central role in immune response—might shape the trajectory of COVID-19 infection, and how immunotherapy can shed light on treatment of the disease. Already a leader in immunotherapy research and treatment, Penn Medicine pioneered the groundbreaking …

Continue reading “Avery Posey’s cancer research takes high risks for big rewards”

Posted on

Penn Nanoparticles are Less Toxic to T Cells Engineered for Cancer Immunotherapy

New cancer immunotherapies involve extracting a patient’s T cells and genetically engineering them so they will recognize and attack tumors. This type of therapy is not without challenges, however. Engineering a patient’s T cells is laborious and expensive. And when successful, the alterations to the immune system immediately make patients very sick for a short …

Continue reading “Penn Nanoparticles are Less Toxic to T Cells Engineered for Cancer Immunotherapy”